Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. We launched Oxtellar XR (extended release oxcarbazepine), our first epilepsy product, in the first quarter of 2013 and anticipate the launch of a second epilepsy product, Trokendi XR (extended release topiramate), in the third quarter of 2013, and are developing multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.72 |
| Quarterly EPS Est: | -0.68 |
| PEG Ratio: | -.06 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

